Experimental allergic encephalomyelitis (EAE) was induced in Buffalo rats by immunization with syngeneic spinal cord homogenate in complete adjuvant. EAE, an autoimmune disease of the central nervous system (CNS), is regarded as a model for multiple sclerosis. When severe paresis had developed, rats were treated with high-dose total body irradiation (TBI) and transplanted with syngeneic BM from healthy donors. Nine Gy TBI followed by syngeneic BMT greatly accelerated recovery of paresis compared with untreated controls. In 6-33% of the treated animals a relapse of EAE was observed shortly after treatment. Reimmunization 20 days after treatment, resulted in a relapse in 12-44% of the rats. Employing the maximally tolerated dose of TBI (10 Gy) did not significantly alter the incidence of spontaneous or induced relapses. Furthermore, it was shown that irradiation of the CNS only was not sufficient for the induction of complete regression of paresis. The origin of the cells responsible for these relapses is discussed, as is the importance of reimmunization in evaluating the effect of treatment of experimental autoimmune disease.
Download full-text PDF |
Source |
---|
JMIR Diabetes
January 2025
Research Institute, BC Children's Hospital, Vancouver, BC, Canada.
Background: Beyond physical health, managing type 1 diabetes (T1D) also encompasses a psychological component, including diabetes distress, that is, the worries, fears, and frustrations associated with meeting self-care demands over the lifetime. While digital health solutions have been increasingly used to address emotional health in diabetes, these technologies may not uniformly meet the unique concerns and technological savvy across all age groups.
Objective: This study aimed to explore the mental health needs of adolescents with T1D, determine their preferred modalities for app-based mental health support, and identify desirable design features for peer-delivered mental health support modeled on an app designed for adults with T1D.
Rheumatology (Oxford)
January 2025
Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy.
Objectives: To assess the lung involvement in patients with Still's disease, an inflammatory disease assessing both children and adults. To exploit possible associated factors for parenchymal lung involvement in these patients.
Methods: A multicentre observational study was arranged assessing consecutive patients with Still's disease characterized by the lung involvement among those included in the AIDA (AutoInflammatory Disease Alliance) Network Still's Disease Registry.
J Food Sci
January 2025
Department of Food Science, Cornell University, Ithaca, New York, USA.
This study was intended to provide a novel process that fills a knowledge gap in relation to the enhancement of pulses utilization. The primary goal was to develop an experimental framework for using a high-pressure supercritical fluid extruder (SCFX) as a continuous bioreactor to produce off-flavor reduced and functionally superior pulse flours and protein concentrates in a single step. The current study focused on using SCFX processing to remove off-flavor from pulse flour and protein concentrates, enhancing the quality, acceptability, and marketability of pulse-based products.
View Article and Find Full Text PDFJ Food Sci
January 2025
Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
This study aimed to investigate the potential hypoglycemic mechanism of red ginseng acidic polysaccharides (RGAP) from the perspective of fatty acid (FA) regulation. A high-glucose/high-fat diet in conjunction with streptozotocin administration was employed to establish type 2 diabetes mellitus (T2DM) rat models, and their fecal FAs were detected using the liquid chromatography-mass spectrometry (LC-MS) method. RGAP treatment alleviated the polyphagia, polydipsia, weight loss, and hyperglycemia observed in T2DM rats.
View Article and Find Full Text PDFCancer Sci
January 2025
Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.
CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. CBA-1205 demonstrates potent antitumor activity in multiple tumor models, making it a potential treatment option for DLK1-expressing cancers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!